BeiGene (BGNE) - Stock Price & Dividends
Exchange: USA Stocks • Country: Cayman Islands • Currency: USD • Type: Common Stock • ISIN: US07725L1026
BeiGene, Ltd. is a global biotechnology company that specializes in developing and distributing oncology medications. They offer a broad range of products for various types of cancers, including blood cancers, solid tumors, and leukemias. Their flagship products like BRUKINSA and Tislelizumab have made significant strides in cancer treatment.
Aside from their current pharmaceuticals, BeiGene, Ltd. is actively working on expanding their portfolio by developing new drugs to combat different types of cancers. Some of their promising ventures include Zanubrutinib, Ociperlimab, and Surzebiclimab, among others. These developments underline their commitment to advancing cancer treatment options.
Collaboration is key for BeiGene, Ltd., as they have established partnerships with several prominent companies within the industry like Amgen Inc., Novartis AG, and Bristol Myers Squibb company. These collaborations aim to leverage collective expertise and resources to drive innovation and bring more effective treatments to cancer patients.
Founded in 2010 and headquartered in Grand Cayman, the Cayman Islands, BeiGene, Ltd.'s dedication to oncology research and development is evident through their diverse product pipeline and strategic alliances. To learn more about their initiatives, you can visit their website at https://www.beigene.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
BGNE Stock Overview
Market Cap in USD | 17,438m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2016-02-03 |
BGNE Stock Ratings
Fundamental | -5.63 |
Dividend | - |
Growth 5y | -0.26 |
Rel. Performance vs Sector | -5.78 |
Analysts | 4.57/5 |
Fair Price Momentum | 135.77 USD |
Fair Price DCF | - |
BGNE Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
BGNE Growth Ratios
Growth 12m | -28.33% |
Growth Correlation 12m | -69% |
Growth Correlation 3m | -18% |
CAGR 5y | 2.50% |
Sharpe Ratio 12m | -0.67 |
Alpha vs SP500 12m | -56.28 |
Beta vs SP500 5y weekly | 0.87 |
ValueRay RSI | 40.36 |
Volatility GJR Garch 1y | 59.87% |
Price / SMA 50 | -1.06% |
Price / SMA 200 | -13.47% |
Current Volume | 104.1k |
Average Volume 20d | 211.6k |
External Links for BGNE Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of March 29, 2024, the stock is trading at USD 156.39 with a total of 104,129 shares traded.
Over the past week, the price has changed by -4.47%, over one month by -12.38%, over three months by -12.86% and over the past year by -28.90%.
According to ValueRays Forecast Model, BGNE BeiGene will be worth about 150.5 in March 2025. The stock is currently trading at 156.39. This means that the stock has a potential downside of -3.77%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 274.6 | 75.6% |
Analysts Target Price | 292.5 | 87.1% |
ValueRay Target Price | 150.5 | -3.77% |